What’s in the news from ASCO this year?

So there is no “revolutionary news” in relation to prostate cancer being presented at the annual meeting of the American Society of Medical Oncology (ASCO) in Chicago this year: no results of major phase III trials and no other critical new data that is likely to change physicians’ current practices when they get back home to their clinics. … READ MORE …

President Trump signs “right to try” legislation into law

The issue as to whether the new, so-called “right-to-try” legislation is a good idea or not is contentious and your sitemaster has no interest in getting into that discussion. What is a fact is that it has now been signed into law. … READ MORE …

Immunotherapy for men on active surveillance?

So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …

“Getting off biopsy train in prostate cancer”

“Getting off biopsy train in prostate cancer” is the title of the latest article by Howard Wolinsky (a long-time active active surveillance patient) on the MedPage Today web site. We recommend it to your attention. … READ MORE …

How many men are really benefiting from genome-targeted prostate cancer treatment?

The answer to that question, at present, is that we don’t know — but it’s probably very few indeed compared to all the men who have progressive forms of prostate cancer. … READ MORE …

Upcoming clinical trial of PSMA-linked lutetium-177 in recurrent mCRPC

According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Low-dose abiraterone with food proves its worth in small Phase II trial

We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …